Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q4 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc. presented to its investors.
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, particularly through its novel therapeutic targeting toxic amyloid beta oligomers.
In its latest earnings report, Acumen Pharmaceuticals highlighted the completion of enrollment for its Phase 2 ALTITUDE-AD study, which investigates the efficacy of its lead candidate, sabirnetug, for early Alzheimer’s disease. The company also reported positive topline results from a Phase 1 study on a subcutaneous formulation of sabirnetug, supporting further development.
Financially, Acumen reported a cash reserve of $231.5 million as of December 31, 2024, which is expected to sustain its operations until the first half of 2027. The company experienced an increase in research and development expenses, totaling $93.8 million in 2024, primarily due to the ALTITUDE-AD clinical trial. This contributed to a net loss of $102.3 million for the year, up from $52.4 million in the previous year.
Acumen’s strategic focus remains on advancing sabirnetug through clinical trials, with anticipated topline results from the Phase 2 study expected in late 2026. The company is committed to redefining the standard of care in early Alzheimer’s disease through innovative approaches and disciplined execution.